Prothena Presents Pipeline Update Highlighting Two Partnered Phase 3 Programs

• Prothena achieved a $50 million Phase 3 enrollment milestone for coramitug, its partnered treatment for transthyretin amyloid cardiomyopathy.
• Strategic partnerships have generated $650 million to date, with approximately $2.25 billion in potential downstream milestones across three partnered programs.
• Phase 3 trials of Parkinson’s treatment prasinezumab and coramitug are ongoing, with completion expected in 2029.
• Alzheimer’s treatment moponetug is expected to complete its Phase 2 TargetTau-1 trial in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prothena Corporation plc published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.